| Product Code: ETC6195518 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview |
3.1 Austria Country Macro Economic Indicators |
3.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle |
3.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces |
3.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about alpha-1 antitrypsin deficiency (AATD) and its treatment options |
4.2.2 Rising prevalence of AATD in Austria |
4.2.3 Advancements in medical technology leading to improved AATD augmentation therapies |
4.3 Market Restraints |
4.3.1 High cost associated with AATD augmentation therapy |
4.3.2 Limited reimbursement policies for AATD treatment in Austria |
4.3.3 Stringent regulatory requirements for approval of AATD therapies |
5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends |
6 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types |
6.1 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F |
6.1.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F |
6.1.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F |
6.1.6 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F |
6.1.7 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F |
6.2.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F |
6.2.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F |
6.2.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F |
6.3.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F |
6.3.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F |
6.3.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F |
6.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
7 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics |
7.1 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries |
7.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries |
8 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators |
8.1 Patient adherence rate to AATD augmentation therapy |
8.2 Number of healthcare providers trained in AATD diagnosis and treatment |
8.3 Research and development investment in new AATD therapies |
8.4 Patient quality of life improvements following AATD therapy |
8.5 Rate of diagnosis of AATD in Austria |
9 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment |
9.1 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape |
10.1 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024 |
10.2 Austria Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here